Table 2.
Demographic data, correlation with antiendomysium antibodies, endoscopic and histological findings of duodenal biopsies for the positive individuals
| Age | Gender | IgA EmA | Biopsy | IEL | Endoscopy | |
| Celiac at diagnosis | ||||||
| CPA | 28 | F | Positive | III-C | > 40 | Scalloped folds, nodularity |
| CBO | 38 | F | Positive | III-C | 40 | Mosaic pattern |
| NHF | 41 | F | Positive | III-C | > 40 | Nodularity, atrophic areas |
| AHR | 42 | M | Positive | III-C | 45 | Erosions, edema |
| HB | 61 | M | Negative | III-C | > 40 | Decreased folds |
| GFD transgression | ||||||
| GSCS | 10 | M | Positive | III-C | 55 | Decreased folds, atrophic areas |
| ALM | 19 | F | Positive | III-A | NC | Atrophic areas |
| VC | 23 | F | Positive | III-C | > 40 | Atrophic areas |
| FA | 23 | M | Positive | III-C | 35 | Decreased folds, atrophic areas |
| LGH | 31 | F | Positive | III-A | 35 | Decreased folds |
| RK | 38 | F | Positive | III-C | > 50 | Atrophic areas |
| First-degree relatives | ||||||
| LGS | 21 | F | Positive | I | 38 | Normal |
| RG | 48 | F | Positive | III-C | 48 | Atrophy of folds |
| ERA | 52 | F | Negative | R | R | R |
| Dyspepsia | ||||||
| EJMS | 21 | F | Positive | III-A | 50 | Atrophy |
| LA | 26 | F | Positive | III-C | > 40 | Scalloped folds, areas of atrophy |
EmA: Antiendomysium; IEL: Percent of intraepithelial lymphocytes; NC: Not counted; R: Recommended.